Levothyroxine Sodium Tablets Recalled Due to Subpotency Nationwide
Accord Healthcare is recalling 4,872 bottles of Levothyroxine Sodium Tablets nationwide due to subpotency. The tablets contain less active ingredient than labeled.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. Subpotent thyroid medication poses a risk to patients requiring accurate dosing, but the absence of reported harm limits the score to 3 per the rubric.
Plain-English summary
Accord Healthcare, Inc. is recalling 4,872 bottles of Levothyroxine Sodium Tablets, USP, 50 mcg, due to subpotency. The affected lot is Lot # D2400547 with an expiration date of February 2026. The product was manufactured by Intas Pharmaceuticals Limited in India and distributed nationwide in the United States.
The tablets contain less levothyroxine sodium than the labeled amount. Levothyroxine is used to treat thyroid conditions and requires accurate dosing for effective treatment.
Patients who obtained medication from the affected lot should contact their pharmacist or healthcare provider with questions.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Category
- Drug
- Hazard
- subpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # D2400547
- Exp Date: 02/2026
UPCs (12)
- 0316729447157
- 0316729449151
- 0316729452151
- 0316729454155
- 0316729453158
- 0316729448154
- 0316729451154
- 0316729457156
- 0316729450157
- 0316729456159
- 0316729458153
- 0316729455152
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Subpotent Content
FDA (Drugs) · 2026-04-01
- HighLevothyroxine Tablets Recall for Wrong Strength Product Mix-Up
FDA (Drugs) · 2026-01-21
- HighLevothyroxine Sodium Tablets Recalled for Subpotency Issue Nationwide
FDA (Drugs) · 2025-10-15
- ModerateLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Content
FDA (Drugs) · 2025-07-23
- HighLevothyroxine Sodium Tablets Recalled Due to Below-Specification Potency
FDA (Drugs) · 2025-07-23
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27